Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
torasemide (Sinsan Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Sinsan Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**DYLOOP** is a Sinsan Pharmaceuticals oral tablet brand containing **torasemide**, a small-molecule loop diuretic. Torasemide inhibits the sodium-potassium-chloride cotransporter in the thick ascending limb of the loop of Henle, increasing urinary sodium, chloride, and water excretion. DYLOOP is marketed in 10 mg and 20 mg tablet strengths for management of essential hypertension and edema associated with congestive heart failure, renal disease, or hepatic disease.
- Brand names
- DYLOOP
- Other names
- torsemide
02
Targets
NKCC2 (Sodium-potassium-chloride cotransporter 2)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on torasemide (Sinsan Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on torasemide (Sinsan Pharmaceuticals).